State Street Corp Checkpoint Therapeutics, Inc. Transaction History

State Street Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $3,647 - $6,655	-3,760 Reduced 1.78%	207,179 $213,000
Q1 2022 May 16, 2022	BUY	$1.53 - $3.25 $28,262 - $60,034	18,472 Added 9.6%	210,939 $373,000
Q2 2021 Aug 16, 2021	SELL	$2.36 - $3.2 $1.56 Million - $2.11 Million	-660,520 Reduced 77.44%	192,467 $568,000
Q1 2021 May 17, 2021	BUY	$2.6 - $4.16 $187,714 - $300,343	72,198 Added 9.25%	852,987 $2.68 Million
Q4 2020 Feb 16, 2021	BUY	$2.19 - $2.96 $253,715 - $342,921	115,852 Added 17.42%	780,789 $2.07 Million
Q3 2020 Nov 10, 2020	BUY	$1.62 - $4.24 $127,581 - $333,916	78,754 Added 13.44%	664,937 $1.78 Million
Q2 2020 Aug 14, 2020	BUY	$1.19 - $2.27 $82,612 - $157,587	69,422 Added 13.43%	586,183 $1.16 Million
Q1 2020 May 11, 2020	BUY	$1.11 - $2.43 $573,604 - $1.26 Million	516,761 New	516,761 $780,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $299M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.